TrialCancer chemotherapy and pharmacology2024

Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.

Apostolia Maria Tsimberidou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.